France supports Belgium's push to block US destruction of contraceptives
The contraceptives – including intrauterine devices (IUDs), implants and pills – were bought under public health programmes run by the US Agency for International Development (USAID).
Since January, the supplies have been sitting in a warehouse in Geel, Belgium, after the Trump administration froze and then cancelled funding for reproductive health projects.
The products, which were meant for use in low- and middle-income countries, were being stored as part of USAID's supply chain, managed by its logistics contractor Chemonics.
Several media outlets have reported that the material may soon be transferred and incinerated in France, though no final decision has been confirmed.
A diplomatic source told RFI that France 'firmly supports the Belgian authorities' desire to find a solution to avoid the destruction of the contraceptives' and is 'following the situation closely'.
The source added that France had 'no information about any transfers that have taken place'.
A US State Department spokesperson told the French news agency AFP that a preliminary decision had been made to destroy certain "abortifacient contraceptives" from USAID contracts, adding that no HIV medication or condoms would be affected.
The destruction is expected to cost $167,000. The stock is valued at $9.7 million.
French left urges Macron not to be complicit in US plan to bin contraceptives
Redistribution offers rejected
Several global organisations say they offered to collect and redistribute the supplies free of charge, but were turned down by US authorities.
The International Planned Parenthood Federation (IPPF) said it proposed to recover the products in Brussels, transport them to its Dutch warehouse for repackaging, and then send them to countries in need.
MSI Reproductive Choices, a UK-based group, told RFI it had offered to cover all the costs involved, including rebranding.
'We would have removed the stars from the USAID logo. It would have cost the US taxpayer nothing, nor the government,' said Sarah Shaw, MSI's advocacy director.
'We were told the US government would only sell the supplies at their purchase price. This is a situation we have never seen before.'
Shaw estimated the stock would have covered Senegal's contraception needs for three years.
The UN's sexual and reproductive health agency, UNFPA, also offered to buy the contraceptives but was turned down.
'This suggests the problem is not legal, but ideological,' Shaw said. 'It is a clear refusal to allow these contraceptives to be given to women in need. This US administration simply does not recognise their right to contraception.'
The US State Department has described the items as 'abortifacient' – a term commonly used by anti-abortion activists to describe IUDs and other hormonal contraceptives.
Since January, the Trump administration has banned any US funding to NGOs that support or promote access to abortion, even indirectly.
What's stopping more men in France from getting vasectomies?
French firm denies involvement
Media reports have identified Veolia, a French waste management firm, as a possible contractor for the incineration. But the company told RFI it only has a framework agreement with Chemonics to handle expired products.
'The stock mentioned in Belgium is not part of this agreement,' Veolia's press office said. 'We are not responsible for its management.'
Activist Danièle Gaudry, from the coalition Abortion in Europe – Women Decide, told RFI the timing of any transfer from Belgium to France remains unknown. 'We still don't know the date it will happen, and we're still trying to identify the company,' she said.
France's parliament approves free contraception to be extended to women up to the age of 25
Lawmakers urge action
On Saturday, French Greens leader Marine Tondelier and a group of female MPs urged President Emmanuel Macron to intervene, calling the plan 'an affront to the fundamental principles of solidarity, public health and sexual and reproductive rights that France is committed to defending'.
They asked him not to become 'complicit, even indirectly, in retrograde policies' and to support NGOs ready to redistribute the contraceptives.
Sarah Durocher, president of the French Family Planning association, said France had a responsibility to act.
'A government that proudly enshrines the right to abortion in its constitution must also defend access to contraception beyond its borders,' she said, in a statement issued by IPPF.
The Elysée has yet to comment on the case.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
New study reveals which diets will help avoid illness in later life
What you eat could determine how many chronic illnesses you get later in life, scientists warn. Research has revealed that a healthy diet - such as the Mediterranean diet which is high in plants, fish and unsaturated fats - could slow down the accumulation of chronic diseases including dementia in older adults. Inflammatory diets full of processed meat and sugar may accelerate it. Researchers from Karolinska Institutet in Sweden studied four diets to investigate their impact on chronic diseases in older adults. Three of the diets studied were healthy and focused on the intake of vegetables, fruit, whole grains, nuts, legumes, unsaturated fats and reduced intake of sweets, red meat, processed meat and butter/margarine. The fourth diet, however, was pro-inflammatory and focused on red and processed meat, refined grains and sweetened beverages, with lower intake of vegetables, tea and coffee. Researchers followed the diets of 2,400 adults aged 60 and older in Sweden for 15 years and tracked their chronic conditions. Dietary intake was measured using food frequency questionnaires, and adherence to four dietary patterns: the Empirical Dietary Inflammatory Index (EDII), AHEI, the Alternate Mediterranean Diet (AMED), and the MIND (Mediterranean–DASH Intervention for Neurodegenerative Delay). Multimorbidity was defined as the number of chronic diseases and grouped by organ system - musculoskeletal, cardiovascular, and neuropsychiatric. The results published in the journal Nature Aging revealed those who followed the healthy diets had a slower development of chronic diseases. For example, long-term adherence to healthy dietary patterns, particularly the AMED, AHEI, and MIND, was linked to a slower accumulation of chronic diseases in older adults. This applied to cardiovascular disease and dementia, but not to diseases related to muscles and bones. But those who followed the pro-inflammatory diet, on the other hand, increased their risk of chronic diseases. 'Our results show how important diet is in influencing the development of multimorbidity in ageing populations,' said co-first author Adrián Carballo-Casla, postdoctoral researcher at the Aging Research Centre, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet. The protective effects of diet may be explained by reduced inflammation, a key factor in aging-related diseases. Study authors want to further their research by identify the dietary recommendations that may have the greatest impact on longevity and the groups of older adults who may benefit most from them, based on their age, gender, psychosocial background and chronic diseases.
Health Line
3 hours ago
- Health Line
6 Signs Your Parkinson's Disease Is Progressing
People move through the stages of Parkinson's at a different pace. At each stage, treatments are available to help as symptoms progress. The progression of Parkinson's is described in five stages. Stage 1 is when early signs start to appear. Stage 5 describes the final stage of the disease, when a person needs around-the-clock nursing care. For some people, it can take as long as 20 years to move through all the stages. As you move through the stages, your doctor and care team will make changes to your treatment plan. That's why it's important to tell your doctor about any new symptoms or differences in how you feel. 1. Medication not working the way it used to In the early stages, taking medication works well to manage symptoms. But as Parkinson's progresses, your medication may work for shorter periods of time, and symptoms may return more easily. Many people notice a decrease in effectiveness after around 5 years. You may experience involuntary movements or be unable to move at all. If you notice your medication becoming less effective, inform your healthcare provider. They may: change the time of the day and frequency of when you use your medication switch to sustained-release tablets (which release the drug gradually) change the doses prescribe additional medications such as COMT inhibitors, NMDA antagonists, anticholinergic drugs or MAO-B inhibitors add a dopamine agonist in addition to levodopa 2. Increased feelings of anxiety or depression Anxiety and depression have been linked to Parkinson's and may occur before movement issues. Up to 40% of individuals with Parkinson's will experience some form of anxiety, and up to 50% will experience some form of depression. It's possible that changes in your emotional well-being can be a sign of changing physical health as well. If you are more anxious than usual, have lost interest in things, or feel a sense of hopelessness, talk with your doctor. A combination of therapy and medication may be used to help manage symptoms of anxiety and depression. Non-pharmacological complementary approaches can include mindfulness practices and social support. 3. Changes in sleeping patterns As Parkinson's progresses, you may also develop problems with sleep patterns. Alternatively, the onset of sleep disorders can precede movement difficulties. You might wake up often in the middle of the night or sleep more during the day than you do at night. Excessive daytime sleepiness occurs in 30 to 50% of individuals with Parkinson's disease. It may be related to medications or poor sleep. Some ways you may be able to prevent this can include: practicing good sleep hygiene, including a set bedtime and wake-up time getting exposure to light during the day and darkness at night avoiding sedentary activities during the day and getting regular exercise Sleep apnea is also a common sleep disturbance, which occurs in 40% of people with Parkinson's disease. A CPAP machine can help treat it. Another sleep disturbance for people with Parkinson's is rapid eye movement (REM) sleep behavior disorder. This is when you start acting out your dreams in your sleep, such as verbally and physically, which can get uncomfortable — or even dangerous — if someone is sharing your bed. There are medications your doctor can prescribe to help REM sleep behavior disorder, such as melatonin or clonazepam. 4. Involuntary movements One of the most effective and commonly used drugs for Parkinson's is levodopa. Over time, as you need to take higher doses of the medication to work, it can also cause involuntary movements (dyskinesia). Your arm or leg might start moving on its own without your control. Your doctor may adjust your medication dosage or prescribe additional medications, such as amantadine or anticholinergic drugs, to help reduce these involuntary movements. 5. Trouble swallowing Difficulty swallowing may not present initially, but it can happen at any stage. Some people may experience it earlier than others. Signs can include: coughing during or right after eating feeling like food is stuck or not going down properly drooling more frequently trouble keeping food or liquid in your mouth frequently experiencing heartburn or sore throat If you notice any changes in the way swallowing feels, speak to a speech-language pathologist. Your primary care provider can refer you to one. They will interview you about and observe your eating and swallowing. From there, they may recommend training to help strengthen your respiratory muscles and making changes to your food to make it easier to swallow.
Yahoo
4 hours ago
- Yahoo
European regulatory authority adopts positive opinion for Novo Nordisk's Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
Pending European Commission (EC) approval, Alhemo® will become available to all adult and paediatric patients 12 years and older living with severe haemophilia A and moderate or severe haemophilia B without inhibitors. This positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is based on results from the explorer8 trial, which showed that Alhemo® reduced spontaneous and traumatic bleeds for patients living with haemophilia A and B without inhibitors compared with no prophylaxis1. If approved by the EC, Alhemo®, with its pen-injector device, has the potential to be an efficacious and easy-to-use option for patients with haemophilia A and B without inhibitors1-3. Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an update of the Alhemo® (concizumab) label to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors. 'If approved by the European Commission, this label update would extend Alhemo®'s convenient once-daily, under-the-skin administration to patients living with haemophilia without inhibitors, providing an efficacious prophylactic choice,' said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. 'Each person living with haemophilia has individual and evolving needs. With its user-friendly, pre-filled, portable pen, we believe that Alhemo® has the potential to offer even more patients an individualised and flexible treatment.' The positive CHMP opinion is based on the results from the phase 3 explorer8 trial, which met its primary endpoint. The results demonstrated that Alhemo® prophylaxis compared with no prophylaxis treatment led to an 86% reduction and 79% reduction in treated spontaneous and traumatic bleeds for patients living with haemophilia A without inhibitors and haemophilia B without inhibitors1, respectively. In this trial, Alhemo® showed a favourable safety profile in patients with haemophilia A and B without inhibitors1. Patient-Reported Outcome (PRO) data from the explorer8 study further indicated an improvement in health-related quality of life and reduction in treatment burden with Alhemo® treatment compared with no prophylaxis3. Specifically, trends favouring Alhemo® over prophylaxis were observed in the short-form health survey (SF-36v2) and Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) results, in patients with haemophilia A and haemophilia B; these included the change in 'bodily pain' and 'physical functioning' from baseline to week 24 in the survey, and the Haem-A-QoL 'total score' and the 'physical health' domain score3. Treatment preference results showed patients were also in favour of Alhemo® over no prophylaxis or previous treatment, with 70.9% of respondents indicating they prefer Alhemo® over their previous haemophilia treatment3. Following the positive opinion from the CHMP, Novo Nordisk expects the European Commission (EC) to approve the label update within approximately two months. About Alhemo® (concizumab)Alhemo® (concizumab) is an anti-tissue factor pathway inhibitor (TFPI), monoclonal antibody designed to block a protein in the body that stops blood from clotting. By blocking TFPI, Alhemo® ensures the production of thrombin, which helps to clot the blood and prevent bleeding4. Alhemo® is currently approved in Europe5, the United States6, India7, Brazil8 and Switzerland9 for the treatment of adolescents and adults (12 years or older) with haemophilia A and B with inhibitors. In Japan10 and Australia11, Alhemo® is currently approved for the treatment of adolescents and adults (12 years or older) with haemophilia A and B with and without inhibitors. In all approved countries, it is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes. About the explorer8 studyExplorer8 is a multicentre, open-label, randomised, phase 3a clinical trial aimed to establish the efficacy and safety profile of Alhemo® in adults and paediatric patients 12 years of age and older living with congenital severe haemophilia A or moderate or severe haemophilia B without inhibitors1,12. In explorer8, 148 patients were randomly assigned in a 1:2 ratio to receive no prophylaxis (arm 1, n=21) or Alhemo® prophylaxis (arm 2, n=42), and 85 were nonrandomly assigned to receive Alhemo® prophylaxis (arms 3 and 4). The initial loading dose of Alhemo® was 1 mg per kilogram of body weight, followed by 0.2 mg per kilogram daily, and potentially individualised on the basis of concizumab plasma concentration as measured at Week 41,12. The primary analysis was carried out when all patients in arms 1 and 2 completed at least 24 or 32 weeks, respectively, and compared the number of treated spontaneous and traumatic bleeding episodes, measured as annualised bleeding rate, between arms 1 and 21,12. Supportive secondary endpoints, such as percent of patients experiencing zero bleeds, are reported as descriptive results only1,12. The trial is still ongoing in the extension phase and is expected to complete in 20281,12. About haemophiliaHaemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. It is estimated to affect approximately 1,125,000 people worldwide13. Due to the nature of haemophilia being an x-linked recessive disorder, it often presents differently in males compared with females, with roughly 88% of people diagnosed with haemophilia worldwide being male14,15. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and haemophilia B is caused by a missing or defective clotting Factor IX (FIX). About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Ida Schaap Melvold +45 3077 5649idmg@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ _______________________References1. Chowdary P, Angchaisuksiri P, Apte S, et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024;11:e891–e904. doi: 10.1016/S2352-3026(24)00307-7.2. Kahr Rasmussen N, Berg B, Christiansen ASL, et al. The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference. Patient Prefer Adherence. 2024;18:1713–1727. doi: 10.2147/PPA.S470091.3. Angchaisuksiri P, von Mackensen S, Apte S, et al. Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. Res Pract Thromb Haemost. 2025;9:102705. doi: 10.1016/ Matsushita T, Shapiro A, Abraham A, et al. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023;389:783–794. doi: 10.1056/NEJMoa2216455.5. Alhemo® (concizumab): Summary of Product Characteristics. 2024. Available at: Last accessed: July 2025. 6. Alhemo® (concizumab-mtci): Prescribing Information. 2024. Available at: Last accessed: July 2025. 7. CDSCO. List of new drugs (r-DNA origin) approved for import and marketing in India during Jan, 2020 – Apr, 2025 Available at: Last accessed: July 2025. 8. Alhemo® (concizumab): Brazil Product Information. 2025. Available at: Last accessed: July 2025. 9. Alhemo® (concizumab): Switzerland Product Information. 2024. Available at: Last accessed: July 2025. 10. Alhemo® (concizumab): Japanese Product Information. Available at: Latest revision date: July 2025. 11. Alhemo® (concizumab): Therapeutic Goods Administration (TGA) Product Information. 2024. Available at: Last accessed: July 2025. 12. NCT04082429. Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors (explorer8). Available at: Last Accessed: July 2025. 13. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019;171:540–546. doi: 10.7326/M19-1208.14. Centers for Disease Control and Prevention. About Hemophilia. Available at: Last accessed: July 2025. 15. Statista. Distribution of people with bleeding disorders worldwide in 2020, by gender. Available at: Last accessed: July 2025. Attachment PR250725-Alhemo-CHMP-Positive-OpinionSign in to access your portfolio
